Cue Biopharma (CUE) — Financial Flexibility Index
Cue Biopharma (CUE) has a Financial Flexibility Index of -0.49x as of September 2025. Free cash flow of $-9.02 Million (operating CF $-9.02 Million minus capex $0.00) represents 0% of total liabilities ($18.40 Million). Check CUE strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Cue Biopharma Financial Flexibility Index (2015–2024)
Historical Financial Flexibility Index trend for Cue Biopharma across 10 annual periods. See working capital to net assets of Cue Biopharma to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for Cue Biopharma (2015–2024)
Year-by-year free cash flow to debt coverage for Cue Biopharma. For the full company profile including market capitalisation, see market value of Cue Biopharma.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -2.47x | $-36.26 Million | $-36.33 Million | $14.69 Million | ▼ -51.0% |
| 2023 | -1.63x | $-39.96 Million | $-39.96 Million | $24.45 Million | ▼ -0.5% |
| 2022 | -1.63x | $-41.63 Million | $-41.81 Million | $25.60 Million | ▲ +23.2% |
| 2021 | -2.12x | $-37.92 Million | $-38.84 Million | $17.91 Million | ▼ -36.9% |
| 2020 | -1.55x | $-31.90 Million | $-32.49 Million | $20.62 Million | ▲ +14.4% |
| 2019 | -1.81x | $-30.75 Million | $-30.80 Million | $17.02 Million | ▲ +16.2% |
| 2018 | -2.16x | $-24.56 Million | $-26.41 Million | $11.39 Million | ▼ -4.9% |
| 2017 | -2.05x | $-10.99 Million | $-12.19 Million | $5.35 Million | ▲ +58.4% |
| 2016 | -4.94x | $-5.45 Million | $-5.97 Million | $1.10 Million | ▼ -105.7% |
| 2015 | -2.40x | $-903.28K | $-1.66 Million | $376.30K | — |